Guardian Partners’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.07M Sell
7,525
-440
-6% -$66.7K 0.1% 117
2026
Q2
$1.25M Sell
7,965
-126
-2% -$18.9K 0.11% 99
2026
Q1
$1.24M Sell
8,091
-49
-0.6% -$7.51K 0.1% 109
2025
Q4
$1.24M Buy
8,140
+6,000
+280% +$786K 0.1% 117
2025
Q3
$282K Hold
2,140
– – 0.02% 158
2025
Q2
$263K Hold
2,140
– – 0.02% 163
2025
Q1
$236K Sell
2,140
-35
-2% -$3.73K 0.02% 159
2024
Q4
$218K Buy
+2,175
New +$232K 0.02% 159

Other funds holding NVS

Guardian Partners's NVS Position: Q3 2026 in Review

Guardian Partners reduced its Novartis (NVS) stake by 5.5% in Q3 2026, selling an estimated $66.7K and leaving 7,525 shares worth $1.07M. The position accounts for 0.1% of the portfolio, ranked #117.

Guardian Partners first reported a position in NVS in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.25M in Q2 2026. 1,438 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • Guardian Partners held 7,525 shares of Novartis worth $1.07M as of Q3 2026.
  • Guardian Partners sold 440 Novartis shares in Q3 2026, an estimated $66.7K.
  • Novartis made up 0.1% of Guardian Partners's portfolio in Q3 2026, its #117 holding.
  • Guardian Partners first reported a position in Novartis in Q4 2024 and has held it in 8 quarters since.
  • Guardian Partners's Novartis position peaked at $1.25M in Q2 2026.
  • 1,438 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on Guardian Partners's 13F filing for Q3 2026, filed 21 Oct 2026.